Accuray Incorp Stock Price, News & Analysis

Accuray announced that Royal Brisbane and Women's Hospital in Queensland, Australia, has selected two Radixact Systems equipped with ClearRT imaging and Synchrony technology to enhance radiotherapy services. This upgrade will replace older TomoTherapy Systems, allowing for improved precision and efficiency in radiation treatment. RBWH, a leading cancer care facility, aims to increase patient throughput and deliver personalized treatments. The partnership highlights Accuray's commitment to innovation in cancer care.

Accuray Incorporated (NASDAQ: ARAY) announced significant results from its Phase III TomoBreast trial, showing that hypofractionated radiotherapy via the TomoTherapy System preserves long-term heart and lung function in early breast cancer patients. The study revealed a 10-year survival rate free of heart and lung deterioration at 84.5% compared to 66.9% with conventional therapy. The trial involved 123 women and was published in BMC Cancer. The findings suggest that TomoTherapy may reduce side effects and enhance patient recovery times.

Accuray Incorporated (NASDAQ: ARAY) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. The management team is set to engage in a virtual fireside chat on February 16, 2022, at 3:30 PM EST / 12:30 PM PST. This event is designed for BTIG clients and offers opportunities for one-on-one meetings with management. Accuray is dedicated to enhancing radiation therapy innovation to improve patient outcomes across various conditions.

Accuray Incorporated (NASDAQ: ARAY) reported a record net revenue of $116.3 million for Q2 FY2022, up 19% year-over-year. Gross orders reached $85.4 million, a 13% increase. However, net income dropped to $0.2 million from $4.8 million in the prior year, while adjusted EBITDA also fell to $6.8 million from $13.5 million. Operating expenses rose by 18% to $38.6 million. The company faces global supply chain challenges but has strong demand for its new technologies, including ClearRT™ and CyberKnife® products.

Accuray Incorporated (NASDAQ: ARAY) will announce its second-quarter fiscal 2022 financial results on January 26, 2022, after market close. A conference call to discuss the results will be held at 1:30 PM PT / 4:30 PM ET on the same day. Dial-in numbers for the call are provided, along with information about accessing a live webcast and replay. Accuray focuses on innovative radiation therapy solutions to address complex patient needs, enhancing treatment efficiency in oncology and neuro-radiosurgery.

Accuray Incorporated (NASDAQ: ARAY) received approval from Japan's Ministry of Health to market its CyberKnife^® Robotic Radiosurgery System for treating trigeminal neuralgia (TN). This expands access to a high-precision treatment already in use in the U.S. and EIMEA. TN, characterized by severe facial pain, often necessitates ongoing medical care. Notably, 93.5% of patients experience relief from TN after three weeks using CyberKnife. This approval paves the way for potential reimbursement under Japan's health insurance system, enhancing treatment options for TN patients.

Accuray Incorporated (NASDAQ: ARAY) announced valuable findings supporting its CyberKnife robotic radiotherapy platform, which has shown effective treatment for neurological diseases through stereotactic radiosurgery. A recent analysis of over 7,000 patients from Stanford University highlighted the platform's growing acceptance and ability to treat various brain and spinal lesions. The CyberKnife enables precise, non-invasive treatment, potentially improving patient outcomes and quality of life. Advanced features, including AI-driven technology, enhance treatment planning efficiency.

Accuray Incorporated (Nasdaq: ARAY) will participate in Stifel's 2021 Virtual Healthcare Conference on November 16, 2021, at 6:20 am PACIFIC / 9:20 am EASTERN. The management team's presentation can be accessed through the Accuray website post-event, with a replay available for about 90 days. Accuray focuses on innovating radiation therapy solutions aimed at improving patient outcomes in oncology and other complex cases. For more information, visit www.accuray.com.

Accuray Incorporated (NASDAQ: ARAY) reported a record net revenue of $107.4 million for Q1 Fiscal 2022, a significant increase from $85.3 million year-over-year, driven by a strong 39% rise in gross orders totaling $70.0 million. However, the company faced a GAAP net loss of $1.0 million, compared to a net income of $0.4 million in the prior year. Adjusted EBITDA decreased to $5.4 million from $9.0 million. Cash reserves also fell to $105.2 million, down $11.7 million since June 2021, primarily due to bonus payouts and debt repayment.